These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10498538)

  • 1. Proceedings of the University of Texas M. D. Anderson Cancer Center Medical Oncologist Consensus Conference. Future Directions with Herceptin (Trastuzumab) for Breast Cancer. Maui, Hawaii, USA. July 16-18, 1998.
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):1-123; quiz 124-33. PubMed ID: 10498538
    [No Abstract]   [Full Text] [Related]  

  • 2. Herceptin raises its sights beyond advanced breast cancer.
    McNeil C
    J Natl Cancer Inst; 1998 Jun; 90(12):882-3. PubMed ID: 9637135
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimising the Role of Herceptin in Breast Cancer. Symposium proceedings. Monte Carlo, June 19-21, 2000.
    Oncology; 2001; 61 Suppl 2():1-91. PubMed ID: 11758500
    [No Abstract]   [Full Text] [Related]  

  • 4. Herceptin: from the bench to the clinic.
    Colomer R; Shamon LA; Tsai MS; Lupu R
    Cancer Invest; 2001; 19(1):49-56. PubMed ID: 11291556
    [No Abstract]   [Full Text] [Related]  

  • 5. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S; Pickering L; Ellis P
    J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Therapies in the Treatment of Breast Cancer. Proceedings of a meeting. Kailua-Kona, Hawaii, July 19-23, 2000.
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):1-153; quiz 154-65. PubMed ID: 11760720
    [No Abstract]   [Full Text] [Related]  

  • 8. Proceedings of the HER2 State of the Art Conference. 21-23 November 1999. Montreux, Switzerland.
    Ann Oncol; 2001; 12 Suppl 1():1-107. PubMed ID: 11816498
    [No Abstract]   [Full Text] [Related]  

  • 9. Herceptin and the heart--a molecular modifier of cardiac failure.
    Chien KR
    N Engl J Med; 2006 Feb; 354(8):789-90. PubMed ID: 16495390
    [No Abstract]   [Full Text] [Related]  

  • 10. [Trastuzumab. Monoclonal antibody for the treatment of breast cancer].
    Heinzl S
    Med Monatsschr Pharm; 2000 Nov; 23(11):350-2. PubMed ID: 11103587
    [No Abstract]   [Full Text] [Related]  

  • 11. Trastuzumab: designer drug or fashionable fad?
    Freebairn AJ; Last AJ; Illidg TM
    Clin Oncol (R Coll Radiol); 2001; 13(6):427-33. PubMed ID: 11824879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody therapy for breast cancer: herceptin.
    Finn RS; Slamon DJ
    Cancer Chemother Biol Response Modif; 2003; 21():223-33. PubMed ID: 15338747
    [No Abstract]   [Full Text] [Related]  

  • 13. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].
    Beuzeboc P; Scholl S; Garau XS; Vincent-Salomon A; Cremoux PD; Couturier J; Palangié T; Pouillart P
    Bull Cancer; 1999 Jun; 86(6):544-9. PubMed ID: 10417428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 targeted therapy in breast cancer...beyond Herceptin.
    Pal SK; Pegram M
    Rev Endocr Metab Disord; 2007 Sep; 8(3):269-77. PubMed ID: 17899385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical effectiveness of trastuzumab for breast cancer: a systematic review.
    Lewis R; Bagnall AM; Forbes C; Shirran E; Duffy S; Kleijnen J; Riemsma R; ter Riet G
    Health Technol Assess; 2002; 6(13):1-71. PubMed ID: 12137722
    [No Abstract]   [Full Text] [Related]  

  • 17. Trastuzumab in breast cancer.
    Katsumata M; Drebin JA; Greene MI
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470952
    [No Abstract]   [Full Text] [Related]  

  • 18. [Isolated effect of the monoclonal antibody trastuzumab (Herceptin) in a patient with local recurrence of breast carcinoma with HER-2 hyperexpression. ].
    Del Giglio A
    Rev Assoc Med Bras (1992); 2006; 52(4):202. PubMed ID: 16967134
    [No Abstract]   [Full Text] [Related]  

  • 19. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 20. Predicting response to herceptin therapy.
    Lipton A; Leitzel K; Ali S
    Clin Cancer Res; 2004 Mar; 10(5):1559-60. PubMed ID: 15014003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.